Lista de obras -

90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.

artículo científico publicado en 2004

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

artículo científico publicado en 2017

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

artículo científico publicado en 2013

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2014

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

artículo científico publicado en 2014

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

scientific article published on 28 January 2019

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

artículo científico publicado en 2014

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

artículo científico publicado en 2011

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

artículo científico publicado en 2017

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

artículo científico publicado en 2017

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

artículo científico publicado en 2015

Adult Burkitt leukemia and lymphoma

artículo científico publicado en 2004

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect

article

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas

artículo científico publicado en 2009

Antibodies for the treatment of diffuse large cell lymphoma.

artículo científico publicado en 2003

Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.

artículo científico publicado en 2013

B-cell receptor pathway modulators in NHL.

artículo científico publicado en 2015

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

artículo científico publicado en 2016

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

artículo científico publicado en 2020

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 ⬇️

artículo científico publicado el 21 de marzo de 2011

Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers

artículo científico publicado en 2020

CD30: seeing is not always believing

artículo científico publicado en 2015

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2008

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL

artículo científico publicado en 2017

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma ⬇️

artículo científico publicado el 12 de enero de 2011

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

artículo científico publicado en 2009

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

artículo científico publicado en 2014

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

artículo científico publicado en 2018

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.

artículo científico publicado en 2014

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria

artículo científico publicado en 2007

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

scientific article published on 08 September 2017

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort

artículo científico publicado en 2016

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

artículo científico publicado en 2018

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

artículo científico publicado en 2008

Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma

artículo científico publicado en 2008

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

artículo científico publicado en 2009

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

artículo científico publicado en 2019

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

artículo científico publicado en 2012

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

scientific article published on 01 November 2004

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

artículo científico publicado en 2016

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Evaluation and management of lymphoma and leukemia in pregnancy

artículo científico publicado en 2011

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

artículo científico publicado en 2015

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

artículo científico publicado en 2017

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

artículo científico publicado en 2011

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

artículo científico publicado en 2008

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma

artículo científico publicado en 2018

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

artículo científico publicado en 2006

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

artículo científico publicado en 2013

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

artículo científico publicado en 2012

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

artículo científico publicado en 2009

Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study

artículo científico publicado en 2019

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

artículo científico publicado en 2015

High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

artículo científico publicado en 2008

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Hodgkin disease/lymphoma

scientific article published on 01 July 2008

Hodgkin lymphoma

artículo científico publicado en 2011

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

artículo científico publicado en 2012

Hodgkin lymphoma, version 2.2015.

artículo científico publicado en 2015

How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant

artículo científico publicado en 2015

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

artículo científico publicado en 2015

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study

scientific article published on 24 March 2020

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

artículo científico publicado en 2013

Ibrutinib in B-cell Lymphomas

artículo científico

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

artículo científico publicado en 2009

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

artículo científico publicado en 2014

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

artículo científico publicado en 2014

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

artículo científico publicado en 2015

Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States

scientific article published on 10 August 2018

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

artículo científico publicado en 2009

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

artículo científico publicado en 2015

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

artículo científico publicado en 2020

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

artículo científico publicado en 2013

Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.

artículo científico publicado en 2010

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib

artículo científico publicado en 2017

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

artículo científico publicado en 2012

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

artículo científico publicado en 2017

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

artículo científico publicado en 2017

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

artículo científico publicado en 2014

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2013

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

artículo científico publicado en 2016

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

artículo científico publicado en 2010

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.

artículo científico publicado en 2002

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation

artículo científico publicado en 2010

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

artículo científico publicado en 2009

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

artículo científico publicado en 2009

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

artículo científico publicado en 2018

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies

scientific article published on 27 February 2019

Postibrutinib outcomes in patients with mantle cell lymphoma

artículo científico publicado en 2016

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

artículo científico publicado en 2018

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

artículo científico publicado en 2006

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

artículo científico publicado en 2009

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

artículo científico publicado en 2016

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

artículo científico publicado en 2015

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

artículo científico publicado en 2015

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

artículo científico publicado en 2012

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)

scientific article published on 07 June 2019

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

artículo científico publicado en 2015

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

artículo científico publicado en 2014

Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose

artículo científico publicado en 2016

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

artículo científico publicado en 2011

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

artículo científico publicado en 2015

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

artículo científico publicado en 2010

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

artículo científico publicado en 2007

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

artículo científico publicado en 2018

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

artículo científico publicado en 2016

Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.

artículo científico

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

artículo científico publicado en 2015

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2013

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

artículo científico publicado en 2013

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2015

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo

artículo científico publicado en 2010

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

scientific article published on 21 December 2018

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 4 de marzo de 2011

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

artículo científico publicado en 2014

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

artículo científico publicado en 2015

Treatment strategies in mantle cell lymphoma

artículo científico

Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation

artículo científico publicado en 2018

Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma ⬇️

artículo científico publicado el 1 de enero de 2010

Lista de obras de

90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Adult Burkitt leukemia and lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas

Antibodies for the treatment of diffuse large cell lymphoma.

Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.

B-cell receptor pathway modulators in NHL.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 ⬇️

Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers

CD30: seeing is not always believing

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma ⬇️

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Evaluation and management of lymphoma and leukemia in pregnancy

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Hodgkin disease/lymphoma

Hodgkin lymphoma

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Hodgkin lymphoma, version 2.2015.

How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib in B-cell Lymphomas

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.